Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on February 3, 2015. The filing documents corporate governance actions taken in connection with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and corporate structural changes rather than financial performance data.
Material Changes
- Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State on February 3, 2015, effective upon the closing of the IPO.
- Amended and Restated Bylaws: Adopted by the Company on February 3, 2015, effective upon the closing of the IPO.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the adoption of new corporate charter documents.
Investor Verification Checklist
- Verify the exact terms of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for details on authorized share capital and voting rights.
- Review the Amended and Restated Bylaws (Exhibit 3.2) for changes to board composition, meeting procedures, and corporate governance rules.
- Confirm the final closing date and share price of the IPO referenced in the filing.